| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00775-008-0354-Y |
| P698 | PubMed publication ID | 18320241 |
| P50 | author | Keunhong Jeong | Q39438409 |
| Junghun Suh | Q112240041 | ||
| P2093 | author name string | Min Gyum Kim | |
| Sang Ho Yoo | |||
| Tae Yeon Lee | |||
| Woo Suk Chei | |||
| Jae Young Ahn | |||
| P2860 | cites work | Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells | Q24607640 |
| Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients | Q24631987 | ||
| A specific amyloid-beta protein assembly in the brain impairs memory | Q28854597 | ||
| Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis | Q29547501 | ||
| Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 | ||
| Protein-cleaving catalyst selective for protein substrate | Q31118066 | ||
| Peptide-cleaving catalyst selective for peptide deformylase | Q31149040 | ||
| A novel MALDI LIFT-TOF/TOF mass spectrometer for proteomics | Q33187567 | ||
| Angiotensin-cleaving catalysts: conversion of N-terminal aspartate to pyruvate through oxidative decarboxylation catalyzed by Co(III)cyclen | Q33214927 | ||
| Peptide-cleaving catalyst selective for melanin-concentrating hormone: Oxidative decarboxylation of N-terminal aspartate catalyzed by Co(III)cyclen | Q33250015 | ||
| Therapeutic approaches to protein-misfolding diseases | Q34285075 | ||
| Protein chemistry. In the footsteps of alchemists | Q34323404 | ||
| In silico study of amyloid beta-protein folding and oligomerization | Q34374164 | ||
| Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers | Q34396204 | ||
| Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways | Q34468169 | ||
| Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice | Q34577455 | ||
| Synthetic artificial peptidases and nucleases using macromolecular catalytic systems | Q35177330 | ||
| Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes | Q35855088 | ||
| Kinetics and thermodynamics of amyloid fibril assembly | Q36596626 | ||
| Pancreatic amylin content in human diabetic subjects and its relation to diabetes | Q42557258 | ||
| Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases | Q45072759 | ||
| Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. | Q46081255 | ||
| Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. | Q52490197 | ||
| The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. | Q52534249 | ||
| Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. | Q52575906 | ||
| Cleavage agents for soluble oligomers of amyloid beta peptides. | Q53533591 | ||
| Facile intramolecular hydrolysis of dipeptides and glycinamide. | Q54528667 | ||
| Fluorescamine: A Reagent for Assay of Amino Acids, Peptides, Proteins, and Primary Amines in the Picomole Range | Q70513064 | ||
| High-frequency oscillations in circulating amylin concentrations in healthy humans | Q73532668 | ||
| Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives | Q83131276 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 693-701 | |
| P577 | publication date | 2008-03-05 | |
| P1433 | published in | Journal of Biological Inorganic Chemistry | Q3186899 |
| P1476 | title | Cleavage agents for soluble oligomers of human islet amyloid polypeptide | |
| P478 | volume | 13 |
| Q57471906 | Amide Bond Activation of Biological Molecules |
| Q37387617 | Application of metal coordination chemistry to explore and manipulate cell biology |
| Q48157762 | Catalytic Metallodrugs: Substrate-Selective Metal Catalysts as Therapeutics. |
| Q35846078 | Catalytic metallodrugs based on the LaR2C peptide target HCV SLIV IRES RNA. |
| Q33698143 | Cyclen-hybrid compound captures copper to protect INS-1 cells from islet amyloid polypeptide cytotoxicity by inhibiting and lysing effects |
| Q89823393 | Degradation of proteins by PROTACs and other strategies |
| Q34775956 | Metallotherapeutics: novel strategies in drug design |
| Q33775775 | New chelating ligands for Co(III)-based peptide-cleaving catalysts selective for pathogenic proteins of amyloidoses |
| Q39437903 | Protective effects of cleavage agents on INS-1 cells against h-IAPP-induced apoptosis |
| Q46330675 | Proteolytic activity of Co(III) complex of 1-oxa-4,7,10-triazacyclododecane: a new catalytic center for peptide-cleavage agents |
| Q37371607 | Target-directed catalytic metallodrugs |
| Q36106851 | Targeted catalytic inactivation of angiotensin converting enzyme by lisinopril-coupled transition-metal chelates |
| Q35247064 | Transfer hydrogenation catalysis in cells as a new approach to anticancer drug design. |
Search more.